The development of an effective HIV vaccine is one of the greatest global health challenges. However despite decades of research, no vaccine has yet been able to elicit protective immunity to HIV. Recently, efforts to develop vaccines against HIV have focused on optimizing the T cell response to vaccination because of the association between T cell immunity and viral control in HIV. However, the molecular correlates of an optimal CD8 T cell response to vaccination remain unclear. This investigation will identify the molecular characteristics of optimal CD8 T cell function after vaccination, using functional genomics, cellular immunology and animal models.
In Aim 1, we will generate genome-wide expression profiles of tetramer-sorted HIV-specific CD8 T cells elicited by three HIV vaccines in current clinical development. We will compare these HIV-specific CD8 profiles to antigen-specific CD8 T cells responding to vaccines against vaccinia virus (VV) - one of the most successful vaccines ever developed. We will identify patterns of genes that are unique to each type of vaccine and signatures that are common to those vaccines, such VV, that induce highly functional CD8 T cells. Candidate mechanisms that confer different functional attributes to each vaccine-induced CD8 T cell response will be identified using detailed computational analyses. This will be the first comprehensive transcriptional analysis of vaccine-induced antigen-specific CD8 T cells, and will identify new molecular correlates of highly functional CD8 T cells. Increasing data suggest that adenovirus (Ad5) vectored vaccines elicit CD8 T cells with limited functionality.
In Aim 2 we will test the hypothesis that genes upregulated in CD8 T cells responding to Ad5-vectored immunogens contribute to their sub-optimal function. Based on our studies in a mouse model, and supplemented with new data from Aim 1, we will evaluate the role of up to 96 candidate regulator genes that are increased in Ad5/HIV-induced CD8 T cells using functional genomic approaches. A series of highly parallel over-expression studies and RNAi-mediated knockdown experiments will validate the role of candidate genes as inhibitory molecules in human CD8 T cells and in a mouse model of Ad5 vaccination. The proposed studies will accelerate HIV vaccine development by discovering new correlates of optimal vaccine-induced T cell immunity, and identifying the mechanisms that govern CD8 T cell function after vaccination.

Public Health Relevance

Despite decades of research, no vaccines have yet been able to generate an immune response that robustly protects against HIV, and we still don't know what type of immune response should be elicited by a protective vaccine. This proposal will use cutting-edge technologies to: 1) survey thousands of genes expressed by immune cells responding to HIV vaccines;2) identify the patterns of genes that characterize the most functional vaccines;and 3) test which of these genes influences the function of the immune system. Information from this study will help identify new tests to evaluate how well vaccines work, and discover new ways to make a stronger immune response to HIV vaccines. PROJECT NARRATIVE Despite decades of research, no vaccines have yet been able to generate an immune response that robustly protects against HIV, and we still don't know what type of immune response should be elicited by a protective vaccine. This proposal will use cutting-edge technologies to: 1) survey thousands of genes expressed by immune cells responding to HIV vaccines;2) identify the patterns of genes that characterize the most functional vaccines;and 3) test which of these genes influences the function of the immune system. Information from this study will help identify new tests to evaluate how well vaccines work, and discover new ways to make a stronger immune response to HIV vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI091493-05
Application #
8718998
Study Section
HIV/AIDS Vaccines Study Study Section (VACC)
Program Officer
D'Souza, Patricia D
Project Start
2010-09-30
Project End
2016-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Godec, Jernej; Cowley, Glenn S; Barnitz, R Anthony et al. (2015) Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation. Proc Natl Acad Sci U S A 112:512-7
Tan, Yan; Tamayo, Pablo; Nakaya, Helder et al. (2014) Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response. Eur J Immunol 44:285-95
Kurachi, Makoto; Barnitz, R Anthony; Yosef, Nir et al. (2014) The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol 15:373-83
Barnitz, R Anthony; Imam, Sabrina; Yates, Kathleen et al. (2013) Isolation of RNA and the synthesis and amplification of cDNA from antigen-specific T cells for genome-wide expression analysis. Methods Mol Biol 979:161-73
Tan, Wendy G; Jin, Hyun-Tak; West, Erin E et al. (2013) Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol 87:1359-72
Butte, Manish J; Lee, Sun Jung; Jesneck, Jonathan et al. (2012) CD28 costimulation regulates genome-wide effects on alternative splicing. PLoS One 7:e40032
Haining, W Nicholas (2012) Travels in time: assessing the functional complexity of T cells. Proc Natl Acad Sci U S A 109:1359-60
Haining, W Nicholas (2012) Thinking inside the box: how T cell inhibitory receptors signal. Nat Med 18:1338-9
Haining, W Nicholas; Pulendran, Bali (2012) Identifying gnostic predictors of the vaccine response. Curr Opin Immunol 24:332-6
Haining, W Nicholas (2012) The numerology of T cell functional diversity. Immunity 36:10-2

Showing the most recent 10 out of 11 publications